Outcome of Pregnancy in the Era of Pegylated Interferon Alpha 2a in Females with Essential Thrombocythemia: An Experience from Qatar

被引：2
作者：
Abu-Tineh, Mohammad [1 ]
Kassem, Nancy [2 ]
Abdulla, Mohammad Abdul-Jaber [3 ,4 ]
Ismai, Omar Mohammad [3 ,4 ]
Ghasoub, Rola [2 ]
Aldapt, Mahmood B. [3 ,4 ]
Yassin, Mohamed A. [3 ,4 ]
机构：
[1] Hamad Med Corp HMC, Dept Med Educ, Doha, Qatar
[2] HMC, Dept Pharm, Natl Ctr Canc Care & Res, Doha, Qatar
[3] HMC, Natl Ctr Canc Care & Res, Dept Oncol Hematol, Doha, Qatar
[4] HMC, BMT Sect, Doha, Qatar
来源：
CASE REPORTS IN ONCOLOGY | 2020年 / 13卷 / 01期
关键词：
Essential thrombocythemia; Myeloproliferative neoplasms; Interferon; PEG-IFN alpha-2A; Pregnancy; POLYCYTHEMIA-VERA; THERAPY;
D O I：
10.1159/000506447
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Myeloproliferative neoplasms are a diversified group of diseases of the hematopoietic stem cell, such as essential thrombocythemia (ET) and polycythemia vera. They are mainly caused by mutations in the following genes: JAK2, CALR, and MPL. All carry an increased risk to transform into acute leukemia or chronic myelogenous leukemia along with thrombosis and hemorrhagic complications. Treatment of such disorders during pregnancy is a challenging footstep, given the high risk of complications for both the mother and the fetus. Here, we report about two pregnant females with ET that has been treated with pegylated interferon alpha with safe and effective outcome.
引用
收藏
页码：336 / 340
页数：5
相关论文
共 27 条
[11]   Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera [J].
How, Chi-Joan ;
Leiva, Orly ;
Bogue, Thomas ;
Fell, Geoffrey ;
Bustoros, Mark ;
Connell, Nathan T. ;
Connors, Jean M. ;
Ghobrial, Irene M. ;
Higgins, Nancy ;
Jessop, Nicholas A. ;
Kuter, David J. ;
Story, Jennifer Lombardi ;
Mullally, Ann ;
Nardi, Valentina ;
Neuberg, Donna S. ;
Styles, Rachel ;
Zwicker, Jeffrey I. ;
Hobbs, Gabriela S. ;
Fogerty, Annemarie E. .
BLOOD, 2019, 134
[12]   Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms [J].
Kiladjian, J-J ;
Chomienne, C. ;
Fenaux, P. .
LEUKEMIA, 2008, 22 (11) :1990-1998
[13]   The renaissance of interferon therapy for the treatment of myeloid malignancies [J].
Kiladjian, Jean-Jacques ;
Mesa, Ruben A. ;
Hoffman, Ronald .
BLOOD, 2011, 117 (18) :4706-4715
[14]  
Langer C, 2005, HAEMATOLOGICA, V90, P1333
[15]  
LENGFELDER E, 1922, LEUKEMIA LYMPHOMA S1, V22, P135
[16]   Interferon alfa treatment for pregnant women affected by essential thrombocythemia: Case reports and a review [J].
Martinelli, P ;
Martinelli, V ;
Agangi, A ;
Maruotti, GM ;
Paladini, D ;
Ciancia, R ;
Rotoli, B .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 191 (06) :2016-2020
[17]  
Milano V, 1996, J MATERN FETAL MED, V5, P74
[18]   Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera [J].
Quintas-Cardama, Alfonso ;
Kantarjian, Hagop ;
Manshouri, Taghi ;
Luthra, Rajyalakshmi ;
Estrov, Zeev ;
Pierce, Sherry ;
Richie, Mary Ann ;
Borthakur, Gautam ;
Konopleva, Marina ;
Cortes, Jorge ;
Verstovsek, Srdan .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (32) :5418-5424
[19]   Interferon α therapy for patients with essential thrombocythemia -: Final results of a phase II study initiated in 1986 [J].
Saba, R ;
Jabbour, E ;
Giles, F ;
Cortes, J ;
Talpaz, M ;
O'Brien, S ;
Freireich, EJ ;
Garcia-Manero, G ;
Kantarjian, H ;
Verstovsek, S .
CANCER, 2005, 103 (12) :2551-2557
[20]   A phase II trial of pegylated interferon α-2b therapy for polycythemia vera and essential thrombocythemia -: Feasibility, clinical and biologic effects, and impact, on quality of life [J].
Samuelsson, Jan ;
Hasselbalch, Hans ;
Bruserud, Oystein ;
Temerinac, Snezana ;
Brandberg, Yvonne ;
Merup, Mats ;
Linder, Olle ;
Bjorkholm, Magnus ;
Pahl, Heike L. ;
Birgegard, Gunnar .
CANCER, 2006, 106 (11) :2397-2405
123